Significance and Outlook of Preoperative Serum Interleukin-1β and Interleukin-6 as Prognostic Factors in Esophageal Cancer

Hattori, Yukio; Tomita, Natsumi; Yoshino, Keiichi; Kajiyama, Yoshiaki

doi:10.4172/2161-069x.1000531

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrast, Łukaszewicz-Zając et al found a stronger predictive value of IL-6 as compared to carcinoembryonic antigen (CEA) levels in EAC patients without chemotherapy [17]. This is in line with data obtained from ESCCs and other gastrointestinal malignancies indicating an association with increased tumor stage and poor prognosis [8][9][10][11][12][13]. In summary, our data support the role of systemic IL-6 levels as potential biomarker in patients with EACs although a distinct stratification for clinicopathological values or an association with overall survival was not found.…”

Section: Plos Onementioning

confidence: 52%

“…Proinflammatory cytokines like interleukin-(IL-) 6 or IL-2 mainly attract and activate other inflammatory cells in the tumor microenvironment [5][6][7]. Both interleukins have been reported to play a role in esophageal squamous cell carcinomas (ESCC) and other gastrointestinal malignancies like gastric cancers [8][9][10][11][12][13][14][15]. However in EACs conflicting results have been reported [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas

et al. 2020

View full text Add to dashboard Cite

Introduction Reflux promotes esophageal adenocarcinomas (EAC) creating a chronic inflammatory environment. EAC show an increasing incidence in the Western World and median survival rates are still low. The main reasons for poor prognosis despite new multimodal therapies are diagnosis of EACs at an already advanced stage and distant metastases. Hence, we wanted to investigate the presence of systemic inflammatory interleukins (IL) and their impact on patient prognosis. Material and methods Systemic expression levels of pro-and anti-inflammatory markers (IL-2, IL-4, IL-6, IL-10, IL-17A and IL-22) in the sera of 43 EAC patients without neoadjuvant radiochemotherapy were measured by flow cytometric analysis. A correlation to clinicopathological data was performed. Log-rank and Cox regression analysis were used to investigate the impact on patient survival. 43 sera of age and gender matched healthy volunteers were used as controls. Results Increased systemic IL-6 (p = 0.044) and lower IL-17A (p = 0.002) levels were found in EAC patients as opposed to controls. A correlation of IL-10 levels with an increased T stage was found (p = 0.020). Also, systemic IL-10 levels were highly elevated in patients with distant metastasis (p<0.001). However, only systemic IL-17A levels had an influence on patient survival in multivariate analysis.

show abstract

Section: Plos Onementioning

confidence: 52%

Section: Introductionmentioning

confidence: 99%

Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas

et al. 2020

View full text Add to dashboard Cite

show abstract

“…IL-6 is upregulated in several malignancies, including melanoma, and higher levels are associated with progression of disease, worse clinical outcomes, and therapeutic resistance [ 6 ]. Increase IL-6 was associated with worse prognosis in a number of cancers [ 7 , 8 ], including pancreatic [ 9 ], esophageal [ 10 ], melanoma, head and neck squamous cell carcinoma [ 11 ], and colon [ 12 , 13 ]. Furthermore, people with cervical cancer are probably has lower chance of surviving than those whose tumors contain low concentrations of IL-6 [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Association Between Interleukin-6 Levels and Lymph Node Metastasis in Bladder Cancer Patients

et al. 2022

View full text Add to dashboard Cite

Background: Bladder cancer (BC) is one of the urological cancers with high prevalence, mortality, morbidity, and expenditure rates. Urothelial malignancies account for about 90% cases of BC, with squamous and adenocarcinomas making up the remaining 10%. Lymph node metastasis (LNM), the most common type of BC metastasis, is generally found in the pelvic lymph nodes. LNM significantly affects the chances of survival and prognosis for patients with BC. It is feasible to stratify and assess the malignancy of the tumor and its response to therapies using potential tumor markers. Interleukin-6 (IL-6) has been observed to be a predictor of metastasis in lymph nodes in BC. The aim of this study was to evaluate the relationship between IL-6 levels and lymph node metastases in BC patients.Methods: Thirty-two BC patients between August 2021 and January 2022 were admitted to this study. Data on patient characteristics, clinical data, TNM staging, and IL-6 levels were collected. Univariate analysis was used in the characteristics of the patients. Results:The total subjects were 32 with 15 results in LNM. The difference in IL-6 levels between the LNM (+) group and the LNM (-) was statistically significant by Fisher's exact test (P = 0.041) and Mann-Whitney U tests (P = 0.003). Conclusions:The BC patients who had lymph node metastases also had higher serum levels of IL-6.

show abstract

Significance and Outlook of Preoperative Serum Interleukin-1β and Interleukin-6 as Prognostic Factors in Esophageal Cancer

Cited by 2 publications

References 19 publications

Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas

Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas

Association Between Interleukin-6 Levels and Lymph Node Metastasis in Bladder Cancer Patients

Contact Info

Product

Resources

About